tRF-22 negatively regulates MXD1 expression by binding to the 3’UTR of MXD1 mRNA, thereby diminishing MXD1’s transcriptional repression of the HIF1A gene and promoting glioma VM formation. The gene discussed is HIF1A; the disease is central nervous system cancer.